Global Parkinson's Disease Treatment Industry (2020 to 2027) - Market Trajectory & Analytics
17 mars 2021 06h23 HE
|
Research and Markets
Dublin, March 17, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the...
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
08 janv. 2018 16h41 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended...
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
02 nov. 2017 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30,...
NeuroDerm to Host Fourth Quarter and 2015 Fiscal Year Financial Results Conference Call on March 31, 2016
22 mars 2016 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, March 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today...